1. Lucasson F, Richette P, Aouad K, Ryussen-Witrand A, Wendling D, Fautrel B, et al. Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6 years. RMD Open. 2022; 8(1):e001986. PMID:
35091462.
Article
2. Baek HJ, Yoo CD, Shin KC, Lee YJ, Kang SW, Lee EB, et al. Spondylitis is the most common pattern of psoriatic arthritis in Korea. Rheumatol Int. 2000; 19(3):89–94. PMID:
10776686.
Article
3. Helliwell PS, Gladman DD, Chakravarty SD, Kafka S, Karyekar CS, You Y, et al. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. RMD Open. 2020; 6(1):e001149. PMID:
32209721.
Article
4. Poddubnyy D, Jadon DR, Van den Bosch F, Mease PJ, Gladman DD. Axial involvement in psoriatic arthritis: An update for rheumatologists. Semin Arthritis Rheum. 2021; 51(4):880–887. PMID:
34198146.
Article
5. Kim HA, Lee E, Park SY, Lee SS, Shin K. Clinical characteristics of patients with psoriatic spondylitis versus those with ankylosing spondylitis: features at baseline before biologic therapy. J Korean Med Sci. 2022; 37(33):e253. PMID:
35996930.
Article